Sang Geun PARK,Hye Gyeong SHIN,Jeong Woo BAE,Hyun Ju CHOI
申请号：
US15569693
公开号：
US20180125785A1
申请日:
2016.04.27
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to a rivastigmine-containing sustained-release pharmaceutical composition and, more specifically, to a rivastigmine-containing sustained-release pharmaceutical composition, which is a sustained-release preparation containing a pH-dependent delayed release phase, wherein, by controlling the release of the pharmaceutical composition to be minimized in the stomach at the initial stage of administration, the pharmaceutical composition can lower the maximum blood concentration (Cmax) compared with existing products while arriving at an effective blood concentration, thereby reducing side effects, and thereafter, maintaining the effective blood concentration through the sustained-release of main ingredients. As a result, the pharmaceutical composition according to the present invention exhibits the same effect as in the existing twice-a-day dosing through only the once-a-day dosing, and can increase the treatment efficiency of patients through the improvement in the convenience of administration of patients.
